Studying the effect of Fexofenadine on patients with irritable bowel syndrome

Evaluation of the efficacy of Fexofenadine in combination with Mebeverine and Mebeverine with placebo in patients with irritable bowel syndrome

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160813029327N20

Enrollment

Registered

2022-04-26

Start date

2022-04-09

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable bowel syndrome. Irritable bowel syndrome

Interventions

Intervention 1: Intervention group: In this group, patients will receive Foxofenadine 180 mg tablets produced by Exir Pharmaceutical Company once a day for 4 weeks plus their standard treatment, which

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with irritable bowel syndrome based on Rome IV criteria Age between 18-65 years old Informed consent

Exclusion criteria

Exclusion criteria: Patients with diabetes, cardiovascular diseases, neurological and psychiatric disorders, hepatic disorders, renal failure, Celiac and colitis Pregnancy and lactation History of drug allergy

Design outcomes

Primary

Measure	Time frame
Abdominal Pain (Severity of pain and Duration of pain). Timepoint: Before intervention and 4 weeks after intervention. Method of measurement: Irritable Bowel Severity Scale (IBSS).;Abdominal distension (Bloating, Swollen or Tight tummy). Timepoint: Before intervention and 4 weeks after intervention. Method of measurement: Irritable Bowel Severity Scale (IBSS).;Satisfaction with fecal excretion. Timepoint: Before intervention and 4 weeks after intervention. Method of measurement: Irritable Bowel Severity Scale (IBSS).;The impact of the IBS on the Patient's Quality of Life. Timepoint: Before intervention and 4 weeks after intervention. Method of measurement: Irritable Bowel Severity Scale (IBSS).;Irritable Bowel Syndrome Severity Score. Timepoint: Before intervention and 4 weeks after intervention. Method of measurement: Irritable Bowel Severity Scale (IBSS).	—

Measure

Time frame

Abdominal Pain (Severity of pain and Duration of pain). Timepoint: Before intervention and 4 weeks after intervention. Method of measurement: Irritable Bowel Severity Scale (IBSS).;Abdominal distension (Bloating, Swollen or Tight tummy). Timepoint: Before intervention and 4 weeks after intervention. Method of measurement: Irritable Bowel Severity Scale (IBSS).;Satisfaction with fecal excretion. Timepoint: Before intervention and 4 weeks after intervention. Method of measurement: Irritable Bowel Severity Scale (IBSS).;The impact of the IBS on the Patient's Quality of Life. Timepoint: Before intervention and 4 weeks after intervention. Method of measurement: Irritable Bowel Severity Scale (IBSS).;Irritable Bowel Syndrome Severity Score. Timepoint: Before intervention and 4 weeks after intervention. Method of measurement: Irritable Bowel Severity Scale (IBSS).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRamin Abrishami

Islamic Azad University

r_abrishami@iaups.ac.ir+98 21 2264 1889

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026